Amgen EVP receives stock, options in insider filing
Amgen Inc. executive vice president and general counsel Jonathan P. Graham reported routine equity compensation changes.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Amgen Inc. executive vice president and general counsel Jonathan P. Graham reported routine equity compensation changes. On May 5, 2026, he received 2,609 shares of common stock at no cost as a grant, increasing his direct holdings to 40,619 shares. The same day, he was granted 17,022 non-qualified stock options with an exercise price of $329.59 per share, exercisable in four equal annual installments starting May 5, 2027 and expiring in 2036. These options relate to an equal number of underlying common shares. On May 6, 2026, 408 shares were disposed of at $329.59 per share to satisfy tax obligations, leaving him with 40,211 shares held directly. The restricted stock units and options vest in four annual installments of 25% each beginning in 2027, and vested RSUs and related dividend equivalents will be settled in common shares on a one-to-one basis.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 408 | $329.59 | $134K |
| Grant/Award | Nqso (Right to Buy) | 17,022 | $329.59 | $5.61M |
| Grant/Award | Common Stock | 2,609 | $0.00 | $0.00 |
Footnotes (3)
- F1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- F2. These shares include 370 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- F3. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
Key Figures
Key Terms
Restricted Stock Units (RSUs) financial
Dividend Equivalents (DEs) financial
non-qualified stock options financial
Equity Incentive Plan financial
tax-withholding disposition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Amgen (AMGN) report for Jonathan P. Graham?
What are the key terms of Jonathan P. Graham’s new Amgen stock options?
How do Jonathan P. Graham’s Amgen restricted stock units (RSUs) vest and settle?
Under which plan were Jonathan P. Graham’s Amgen equity awards granted?
AI-generated analysis. How Rhea-AI works. Not financial advice.